The Development of Screening Assays For Novel Inhibitors Of ARNO And Its Effector
新型ARNO抑制剂及其效应物筛选方法的研究进展
基本信息
- 批准号:8680032
- 负责人:
- 金额:$ 29.56万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2012
- 资助国家:美国
- 起止时间:2012-09-14 至 2015-06-30
- 项目状态:已结题
- 来源:
- 关键词:ADP-ribosylation factor 6AccountingAddressAdhesionsAffectAmericanAmerican Cancer SocietyApoptosisBiochemicalBiologicalBiological AssayBloodBlood VesselsBreastBreast CarcinomaCancer BiologyCause of DeathCell LineageCell ProliferationCell divisionCell physiologyCell surfaceCellular AssayCessation of lifeCollaborationsColonDataDevelopmentDiagnosisDiseaseEffectivenessEndotheliumEpidermal Growth Factor ReceptorEvaluationFamilyGermanyGrowthGuanine Nucleotide Exchange FactorsGuanosine Triphosphate PhosphohydrolasesHeart DiseasesIn VitroInstitutionLOX geneLaboratoriesLibrariesLifeLigandsLungMEKsMalignant NeoplasmsMelanoma CellMolecularMolecular BankMonomeric GTP-Binding ProteinsMutationNIH Program AnnouncementsNeoplasm MetastasisOncogenicPathologic NeovascularizationPathway interactionsPlayPositioning AttributeProstateProteinsRas/RafReceptor ActivationReceptor Protein-Tyrosine KinasesRectumResearchResearch ProposalsResistanceRoleSignal PathwaySkinTherapeuticTherapeutic InterventionThyroid GlandTumor Cell LineUnited StatesUnited States National Institutes of HealthUniversitiesUrinary tractUtahVascular Endothelial Growth FactorsXenograft Modelangiogenesisanticancer activityassay developmentbasecadherin 5cancer therapycell motilitycombatfemale reproductive systemhigh throughput screeninginhibitor/antagonistmelanomamolecular imagingneoplastic cellnovelreceptorscreeningsmall moleculetooltraffickingtumortumor growth
项目摘要
DESCRIPTION (provided by applicant): Cancer is the second leading cause of death in the United States-second only to diseases of the heart-and accounts for about 23% of all deaths. Although significant progress has been made in the treatment of many cancers, it is estimated that in 2010, 569,490 Americans will die from these diseases (Cancer Facts and Figures 2010, American Cancer Society) and there is as yet no efficacious treatment for many forms of cancers. The molecular complexity of cancer makes the identification of additional oncogenic pathways amenable to therapeutic intervention paramount. In June 2010, NIH posted a program announcement (PA-10- 213) for the Development of Assay for High-throughput Screening for Use in Probe and Pre-therapeutic Discovery to encourage the development of novel, scientifically outstanding assays that have the potential to be developed into high-throughput screens (HTS) of relevant, high priority disease targets both for the identification of small molecule tools and therapeutic candidates. Together, we and our collaborators present data that provide compelling evidence that the inhibition of cytohesins, the guanine nucleotide exchange factors that activate Arf family GTPases, produces anticancer activity in vastly different cell lineages. Further, we demonstrate that this inhibition reduces in vitro proliferation and invasion in the context of Ras/Raf/ERK constitutive activation. Mutations of these downstream components of receptor tyrosine kinase signaling pathways have greatly limited the utility and effectiveness of currently available cancer therapies. Therefore, we believe targeting the cytohesin, ARNO, and its effector, Arf6, may produce promising new small molecule inhibitors useful at combating both innate and acquired chemotherapeutic resistance. In this application we seek to specifically address the need defined by NIH and present a strategy to developing assays amenable to a HTS campaign intended for the identification and evaluation of ARNO and/or Arf6 negative modulators. If successful, we will then seek to automate these screens through collaborations with the NIH's recently launched Molecular Libraries and Imaging initiative or other institutions with access to large, diverse compound libraries. In the long term, this strategy promises to identify new small molecule probe and pre-therapeutic compounds against these novel oncogenic targets.
描述(申请人提供):癌症是美国第二大死亡原因,仅次于心脏病,约占所有死亡人数的23%。尽管在许多癌症的治疗方面已经取得了显著的进展,但据估计,在2010年,569,490名美国人将死于这些疾病(Cancer Facts and Figures 2010,American Cancer Society),并且对于许多形式的癌症还没有有效的治疗方法。 癌症的分子复杂性使得鉴定其他致癌途径对治疗干预至关重要。2010年6月,NIH发布了一项计划公告,(PA-10- 213)开发用于探针和治疗前发现的高通量筛选测定法,以鼓励开发新的、科学上杰出的测定法,这些测定法有可能开发成相关的高通量筛选(HTS),高优先级的疾病靶标,用于鉴定小分子工具和治疗候选物。 总之,我们和我们的合作者提供的数据提供了令人信服的证据表明,抑制细胞粘连素,鸟嘌呤核苷酸交换因子,激活Arf家族GTP酶,产生抗癌活性在非常不同的细胞谱系。此外,我们证明,这种抑制作用降低了Ras/Raf/ERK组成性激活的背景下,在体外增殖和侵袭。受体酪氨酸激酶信号通路的这些下游组分的突变极大地限制了目前可用的癌症疗法的效用和有效性。因此,我们相信靶向细胞粘连素ARNO及其效应子Arf 6可能产生有希望的新的小分子抑制剂,可用于对抗先天性和获得性化疗耐药性。 在本申请中,我们寻求具体解决NIH定义的需求,并提出了一种策略,以开发适合HTS活动的测定法,用于鉴定和评估ARNO和/或Arf 6负调节剂。如果成功,我们将寻求通过与NIH最近推出的分子图书馆和成像计划或其他能够访问大型,多样化化合物图书馆的机构合作来自动化这些筛选。从长远来看,这一策略有望确定新的小分子探针和针对这些新的致癌靶点的预治疗化合物。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
DEAN Yaw LI其他文献
DEAN Yaw LI的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('DEAN Yaw LI', 18)}}的其他基金
Identifying a nodal point for G alpha q signaling in eye disease
确定眼部疾病中 G α q 信号传导的节点
- 批准号:
9006784 - 财政年份:2016
- 资助金额:
$ 29.56万 - 项目类别:
Endothelial Toll-Like Receptor Signaling and Inflammation
内皮 Toll 样受体信号转导和炎症
- 批准号:
8577458 - 财政年份:2014
- 资助金额:
$ 29.56万 - 项目类别:
Endothelial Toll-Like Receptor Signaling and Inflammation
内皮 Toll 样受体信号转导和炎症
- 批准号:
8794450 - 财政年份:2014
- 资助金额:
$ 29.56万 - 项目类别:
High Content Sceening for Hereditary Stroke Syndrome
遗传性中风综合症的高内涵筛查
- 批准号:
8577461 - 财政年份:2013
- 资助金额:
$ 29.56万 - 项目类别:
The Role of the Vasculature in the Pathogenesis of Arthritis
脉管系统在关节炎发病机制中的作用
- 批准号:
8685891 - 财政年份:2013
- 资助金额:
$ 29.56万 - 项目类别:
High Content Sceening for Hereditary Stroke Syndrome
遗传性中风综合症的高内涵筛查
- 批准号:
8731282 - 财政年份:2013
- 资助金额:
$ 29.56万 - 项目类别:
High Content Sceening for Hereditary Stroke Syndrome
遗传性中风综合症的高内涵筛查
- 批准号:
8920675 - 财政年份:2013
- 资助金额:
$ 29.56万 - 项目类别:
The Role of the Vasculature in the Pathogenesis of Arthritis
脉管系统在关节炎发病机制中的作用
- 批准号:
8560103 - 财政年份:2013
- 资助金额:
$ 29.56万 - 项目类别:
The Development of Screening Assays For Novel Inhibitors Of ARNO And Its Effector
新型ARNO抑制剂及其效应物筛选方法的研究进展
- 批准号:
8544183 - 财政年份:2012
- 资助金额:
$ 29.56万 - 项目类别:
相似海外基金
Unraveling the Dynamics of International Accounting: Exploring the Impact of IFRS Adoption on Firms' Financial Reporting and Business Strategies
揭示国际会计的动态:探索采用 IFRS 对公司财务报告和业务战略的影响
- 批准号:
24K16488 - 财政年份:2024
- 资助金额:
$ 29.56万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Mighty Accounting - Accountancy Automation for 1-person limited companies.
Mighty Accounting - 1 人有限公司的会计自动化。
- 批准号:
10100360 - 财政年份:2024
- 资助金额:
$ 29.56万 - 项目类别:
Collaborative R&D
Accounting for the Fall of Silver? Western exchange banking practice, 1870-1910
白银下跌的原因是什么?
- 批准号:
24K04974 - 财政年份:2024
- 资助金额:
$ 29.56万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
A New Direction in Accounting Education for IT Human Resources
IT人力资源会计教育的新方向
- 批准号:
23K01686 - 财政年份:2023
- 资助金额:
$ 29.56万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
An empirical and theoretical study of the double-accounting system in 19th-century American and British public utility companies
19世纪美国和英国公用事业公司双重会计制度的实证和理论研究
- 批准号:
23K01692 - 财政年份:2023
- 资助金额:
$ 29.56万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
An Empirical Analysis of the Value Effect: An Accounting Viewpoint
价值效应的实证分析:会计观点
- 批准号:
23K01695 - 财政年份:2023
- 资助金额:
$ 29.56万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Accounting model for improving performance on the health and productivity management
提高健康和生产力管理绩效的会计模型
- 批准号:
23K01713 - 财政年份:2023
- 资助金额:
$ 29.56万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
CPS: Medium: Making Every Drop Count: Accounting for Spatiotemporal Variability of Water Needs for Proactive Scheduling of Variable Rate Irrigation Systems
CPS:中:让每一滴水都发挥作用:考虑用水需求的时空变化,主动调度可变速率灌溉系统
- 批准号:
2312319 - 财政年份:2023
- 资助金额:
$ 29.56万 - 项目类别:
Standard Grant
New Role of Not-for-Profit Entities and Their Accounting Standards to Be Unified
非营利实体的新角色及其会计准则将统一
- 批准号:
23K01715 - 财政年份:2023
- 资助金额:
$ 29.56万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Improving Age- and Cause-Specific Under-Five Mortality Rates (ACSU5MR) by Systematically Accounting Measurement Errors to Inform Child Survival Decision Making in Low Income Countries
通过系统地核算测量误差来改善特定年龄和特定原因的五岁以下死亡率 (ACSU5MR),为低收入国家的儿童生存决策提供信息
- 批准号:
10585388 - 财政年份:2023
- 资助金额:
$ 29.56万 - 项目类别: